İLYAS ÖZTÜRK, SALİHA YILDIRIM, MELİKE POLAT
The Journal of European Internal Medicine Professionals - 2025;3(2):89-95
Diabetic kidney disease represents a leading cause of chronic kidney disease and end-stage renal disease worldwide. The pathogenesis is primarily driven by persistent hyperglycemia, which induces oxidative stress, low-grade chronic inflammation, and activation of profibrotic signaling pathways. These mechanisms promote mesangial expansion, podocyte injury, and tubular epithelial-to-mesenchymal transition, culminating in glomerulosclerosis and tubulointerstitial fibrosis. Fibrosis is a hallmark of progressive diabetic kidney disease, characterized by excessive deposition of extracellular matrix components, leading to structural distortion and progressive decline in glomerular filtration rate.Proteinuria, a key clinical manifestation of diabetic kidney disease, reflects dysfunction of the glomerular filtration barrier and serves as both a marker and mediator of disease progression. Filtered proteins exert direct cytotoxic effects on proximal tubular epithelial cells, inducing proinflammatory and profibrotic responses that exacerbate tubulointerstitial injury and accelerate fibrosis.Despite standard-of-care therapy with renin-angiotensin-aldosterone system blockade, a significant proportion of patients exhibit residual proteinuria and progressive renal fibrosis, underscoring the need for additional therapeutic interventions. Mineralocorticoid receptor overactivation has emerged as a critical driver of renal inflammation and fibrosis in diabetic kidney disease. Finerenone, a novel non-steroidal, selective mineralocorticoid receptor antagonist, has demonstrated potent antifibrotic and antiproteinuric effects by attenuating the transcription of proinflammatory and profibrotic mediators, including transforming growth factor-beta and connective tissue growth factor. Finerenone reduces macrophage infiltration, extracellular matrix accumulation, and fibrosis in glomerular and tubulointerstitial compartments.The landmark FIDELIO-DKD and FIGARO-DKD trials established the efficacy of finerenone in reducing albuminuria and slowing the progression of kidney disease in patients with type 2 diabetes and chronic kidney disease. By directly targeting key pathophysiological mechanisms of renal fibrosis and proteinuria, finerenone offers a novel and evidence-based therapeutic strategy to mitigate kidney disease progression in this high-risk population.
